Sunday, September 27, 2020 11:18:07 AM
SNSS
15:19 09/25/20
Sunesis partner DOT Therapeutics granted FDA orphan designation
The FDA has granted orphan designation to DOT Therapeutics for its treatment of malignant glioma, according to a post to the agency's website.
In March, Dayton Misfeldt, interim CEO of Sunesis, stated along with the company's Q4 earnings report:
"We are also building value in our product pipeline through partnerships.
In December, we partnered vosaroxin with Denovo Biopharma and TAK-580 with DOT Therapeutics-1 to advance these programs to the market." Reference Link
https://thefly.com/landingPageNews.php?id=3166229&headline=SNSS-Sunesis-partner-DOT-Therapeutics-granted-FDA-orphan-designation
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM